GlassScriptPhysician profile
Ann Faucheux
NPI 1841551157
$6,288.38
in general payments reported to CMS, 2019-2025
27 companies · $287 in 2025
The $287 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $811 · 2023: $2,484 · 2024: $2,706 · 2025: $287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,464 · Education: $13.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,463.52 |
| Education | $13.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,849.22 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $597.07 | 2022-2024 | Xifaxan, Trulance |
| Regeneron Healthcare Solutions, INC. | $499.98 | 2022-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $440.09 | 2022-2025 | Entyvio, Eohilia, Gattex |
| Lilly USA, LLC | $380.83 | 2023-2024 | Omvoh |
| Janssen Biotech, INC. | $364.57 | 2023-2024 | Stelara, Simponi Aria, Remicade |
| Pfizer INC. | $361.58 | 2022-2025 | |
| Gilead Sciences, INC. | $358.78 | 2023-2025 | |
| Celgene Corporation | $318.88 | 2022-2024 | Zeposia |
| Genzyme Corporation | $175.57 | 2023-2024 | |
| Intercept Pharmaceuticals, INC. | $127.38 | 2022-2024 | Ocaliva |
| E.R. Squibb & Sons, L.L.C. | $121.88 | 2023 | Zeposia |
| Phathom Pharmaceuticals, INC. | $102.09 | 2024-2025 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $95.50 | 2024-2025 | Iqirvo |
| Celltrion USA INC. | $72.22 | 2024 | Vegzelma, Zymfentra |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $71.75 | 2022-2024 | Watchman Access System |
| Merck Sharp & Dohme LLC | $57.29 | 2023-2024 | Dificid |
| Ferring Pharmaceuticals INC. | $54.04 | 2023-2024 | Rebyota |
| Ardelyx, INC. | $49.06 | 2023 | Ibsrela |
| Organon LLC | $46.10 | 2022-2023 | Renflexis |
| Braintree Laboratories, INC. | $34.48 | 2023 | Sutab, Suflave |
| Madrigal Pharmaceuticals | $28.89 | 2024 | Resmetirom |
| Exelixis INC. | $23.62 | 2022 | |
| Mirum Pharmaceuticals, INC. | $15.60 | 2024 | Livmarli |
| Daiichi Sankyo INC. | $14.99 | 2022 | |
| Aimmune Therapeutics, INC. | $13.82 | 2024 | |
| Ironwood Pharmaceuticals, INC | $13.10 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Faucheux listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.